EGFR and prostate carcinoma: We find that the absence of p50 does not compromise the ability of p50−/− macrophages to phagocytose MC prostate cancer lines and that addition of PSMA or EGFR Ab or the expression of PSMA.CAR10.3 augments phagocytosis by p50-deficient macrophages in both IFNγ and IL-4, the latter mimicking the immune-suppressive tumor microenvironment.